In paediatrics, SCTs are performed for various malignant and non-malignant diseases: leukaemia; inborn errors of metabolism; SCID; and BM failure syndromes. Unrelated cord blood (UCB) is suggested as a good alternative cell source. [1] [2] [3] In the United States, various centres are using UCB as the first alternative when a matched sibling donor is lacking. In Europe, almost all patients are in national or international cohort studies in which cord blood is usually a last alternative (except for inborn errors of metabolisms since 2005). UCB is not widely used within Europe, therefore most published data are from registry studies (Eurocord/EBMT). The paediatric transplant centres in Prague and Utrecht have used cord blood regularly within the same international transplant protocols and use similar supportive care guidelines. In this study, we analysed several parameters for all children who had received UCB transplantation (UCBT) from 2001 to 2007 in these centres related to clinical outcomes. This retrospective analysis is based on data reported to the local databases (Utrecht and Prague). The main end points were (i) EFS, defined as the time from transplant to autologous reconstitution, graft failure, second transplant or death; (ii) overall survival defined as the time from transplant until date of death. Other end points were (i) neutrophil recovery and (ii) acute or chronic GVHD. Neutrophil recovery was defined as the first day of achieving a neutrophil count of X0.5 Â 10 9 /l for three consecutive days. Statistical analysis was performed using uni-and multivariate Cox-proportional hazard regression analyses. The duration of follow-up was the time to the last assessment for survivors. To analyse risk factors for outcomes, we considered variables associated with the recipient (median age at transplant, gender, CMV serology status), the disease (malignant or non-malignant), the cord blood donor (HLA disparity, and median collected total nucleated cell and CD34 þ cell doses) and the transplant (conditioning: chemo-based or TBI-based). Probabilities of EFS and overall survival were calculated using the KaplanMeier estimate; the two-sided log-rank test was used for univariate comparisons.
A total of 47 patients (22 with malignant and 25 with non-malignant diseases) received a UCBT and were included in the study (for patient characteristics, see Table 1 ). Probability of neutrophil engraftment was 98% with a median day of engraftment at þ 22 days (10-58).
Acute GVHD (grades II-IV) was observed in 27% (4.5% grade III, no grade IV), whereas chronic GVHD was seen in 18% (7% extensive) at 2 years. Probabilities of 2 year overall survival and disease/EFS were 71 and 68%, Figure 1b) . In contrast to other studies, median cell dose (nucleated and CD34 þ ) did not influence the outcomes. 4 This is probably because of the relatively high median number of cells in the cord blood grafts used. This relatively high cell dose was probably associated with the low median age in this cohort. HLA-matched grafts, on the other hand, positively influenced the EFS (100 vs 60% for 4-5 of 6 matched grafts). Although the number of patients was low in this series, this result is in line with other studies 1, 5 and suggests that, in the future, when cord blood banks have increased their inventory, the outcomes of UCBT with available matched grafts might further improve. GVHD rates observed in this study are comparable with what was seen in other studies 1,2 using either BM or cord blood.
In conclusion, this dual centre experience shows that the outcomes even with HLA-incompatible UCBT, with relatively high cell doses, for malignant and non-malignant conditions is encouraging. EFS might in the future be positively influenced when more HLA-matched grafts (six of six on intermediate resolution) are available. Matched or mismatched cord blood appears to be a good alternative stem cell source for SCT in malignant as well as in nonmalignant diseases. More studies using uniform transplant protocols and comparison studies (with other alternative cell sources) are warranted to better define the place of UCB in the donor hierarchy. 
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